Last Price$78.59NASDAQ Previous Close - Last Trade as of 4:00PM ET 4/03/20

Today's Change+1.52(1.97%)
Bid (Size)$75.81 (1)
Ask (Size)$79.49 (1)
Day Low / High$77.24 - 79.49
Volume2.2 M

Incyte Says Study on Eczema Drug Meets Primary Endpoint

8:36AM ET 2/19/2020 MT Newswires
Drug maker Incyte (INCY) said Wednesday that the third phase of its clinical trial program testing ruxolitinib cream on eczema met its primary endpoint.

The company said the study showed that patients treated with ruxolitinib achieved clear to almost clear skin after eight weeks, with no new safety issues identified.

The study tested patients at least 12 years of age and suffering from eczema for two years or more.

Price: 79.95, Change: +0.65, Percent Change: +0.82